FDA Approves Apalutamide for Metastatic Castration-Sensitive Prostate Cancers

On September 17, 2019, the U.S. Food and Drug Administration (FDA) approved apalutamide (Erleada, Janssen Biotech, Inc.) for patients with metastatic castration-sensitive prostate cancer (mCSPC). Apalutamide was initially approved in 2018 for patients with non-metastatic castration-resistant prostate cancer.

Read FDA announcement.

Posted 9/18/2019